No

Date

Investors/

Licensee

Service Provider/

Licensor

Assets

Target·Modality

Indication

Stage

Deal Value

(USD Mn)

1

10/28

Novartis

Monte Rosa

Therapeutics

Molecular glue

  (MRT-6160)

vav guanine nucleotide

 exchange factor 1 (VAV1)

Multiple Sclerosis,

Axial Spondyloarthritis,

Myasthenia Gravis,

Cutaneous Lupus

Erythematosus, Psoriasis,

Ulcerative Colitis, Rheumatoid

Arthritis, T-Cell Lymphomas,

Unspecified B-Cell Lymphomas

Phase I

2,250

2

10/7

AstraZeneca

CSPC

Pharmaceutical

Small molecule

(YS-2302018)

lipoprotein A

unspecified cardiovascular disease

Preclinical

2,020

3

10/8

Merck

Mestag

Therapeutics

Reversing Activated

Fibroblast Technology

(RAFT) platform

-

Inflammatory Diseases

Discovery

1,900

4

10/15

Pfizer

TRIANA

Biomedicines

Molecular glue

-

unspecified cancer

Discovery

1,549

5

10/31

AbbVie

EvolveImmune

Therapeutics

Monoclonal Antibody

T Cell Surface Antigen CD2

unspecified solid tumors and hematological malignancies

Discovery

1,465

6

10/29

Biogen

Neomorph

Molecular glue

-

Alzheimer's, rare and

immunological diseases

Discovery

1,450

7

10/10

Ono Pharmaceutical

LigaChem

Biosciences

Monoclonal Antibody

Conjugated

(LCB-97)

neural cell adhesion molecule L1

(L1CAM)

solid tumors

(ovarian cancer and

Pancreatic cancer)

Preclinical

700

8

10/9

Boehringer

Ingelheim

Circle Pharma

First-in-Class Cyclin Inhibitor

cyclin

unspecified cancer

Discovery

607

9

10/24

Roche

Dyno Therapeutics

AAV capsid platform

-

neurological diseases

-

1,000

No.

Date

Acquires

Issuer

주요 파이프라인

금액
(USD Mn)

1

10/4

Recordati

Sanofi

sutimlimab

Type : Monoclonal antibody

Target : Complement C1s Subcomponent

Indication : Idiopathic Thrombocytopenic Purpura,

Kidney Transplant Rejection, Bullous Pemphigoid

Stage : Marketed

1,075

2

10/23

Merck

Modifi Biosciences

Novel Molecules for Glioma

Type : Small molecule

Target : O- 6 methylguanine methyl transferase (MGMT)

Indication : glioma

Stage : Discovery

1,300

3

10/14

Lundbeck

Longboard Pharmaceuticals

bexicaserin

Type : Small molecule

Target : 5-HT2C

Indication : Dravet syndrome

Stage : Phase 3

2,600

4

10/31

GSK

Chimagen Biosciences

CMG1A46

Type : Trispecific antibodies

Target : CD19xCD20xCD3

Indication : NHL, ALL

Stage : Phase 1/2

n/d